Angiosarcoma Clinical Trial
— EVAOfficial title:
Single-arm, Multicenter, Open Label Phase II Trial to Evaluate the Efficacy of Pazopanib in Combination With Paclitaxel in Advanced and Relapsed Angiosarcoma
NCT number | NCT02212015 |
Other study ID # | GISG-06 |
Secondary ID | |
Status | Terminated |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | July 2014 |
Est. completion date | July 1, 2020 |
Verified date | January 2022 |
Source | Heidelberg University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Open-label phase II trial investigating the efficacy and safety of the investigational combination of pazopanib and paclitaxel.
Status | Terminated |
Enrollment | 26 |
Est. completion date | July 1, 2020 |
Est. primary completion date | December 31, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subjects must provide written informed consent prior to performance of study-specific procedures or assessments and must be willing to comply with treatment and follow-up. Note: Procedures conducted as part of the subject's routine clinical management (e.g., blood count, imaging studies) and obtained prior to signing informed consent may be utilized for screening or baseline purposes provided these procedures are conducted as specified in the protocol. - Age = 18 years - Life expectancy > 3 months - Ability to swallow tablets - Histological confirmed angiosarcoma, primary and secondary angiosarcoma (e.g. radiation-induced or angiosarcoma in chronical lymphedema) are eligible. - Tumor must be locally advanced (unresectable) or metastatic. A progression must be documented within a 6-month period prior to screening. - Eastern Cooperative Oncology Group performance status = 2 - At least one measurable skin lesion or one measurable radiological (CT or MRI) target lesion (RECIST 1.1) - Adequate organ system function as described in protocol - A female is eligible to enter and participate in this study if she is either of non childbearing potential (defined in protocol) or childbearing potential with negative pregnancy test within 2 weeks prior to the first dose of study drug and agrees to use adequate contraception (as defined in protocol) during the study and for 30 days after the last dose of study drug. - All sexually active male patients must agree to use adequate methods of birth control (see protocol) throughout the study and for 30 days after the last dose of study drug. Exclusion Criteria: - Patients who need an active treatment for another malignant disease other than angiosarcoma - Prior treatment with taxane within the last 12 months before study entry - History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal sarcomatosis.(see protocol) - Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding (see protocol) - Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product (see protocol) - Presence of uncontrolled infection - QT prolongation interval (QTc) > 480 msec. - Clinically significant cardiovascular disorders within the past 6 months - Major surgery or trauma within 28 days prior to first dose of investigational product and/or presence of any non-healing wound, fracture, or ulcer - Poorly controlled hypertension (see protocol) - Evidence of active bleeding or bleeding diathesis - Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels - Uncontrolled seizures, disorders of the CNS or psychiatric disorders which may put patient safety at risk, prevent giving informed consent or impact the patient's compliance with the use of study medication - Women who are pregnant or breast feeding - Patients who are not able or not willing to interrupt the intake of medications that are not allowed according to study protocol for at least 14 days before start of study medication and for the whole study period - Chemotherapy or radiotherapy within 14 days before start of study medication - Any ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity, except alopecia |
Country | Name | City | State |
---|---|---|---|
Austria | Universitätsklinik Graz | Graz | |
Austria | Universitätsklinik Wien | Wien | |
Germany | Helios-Klinikum Bad Saarow | Bad Saarow | |
Germany | Helios Klinikum Berlin-Buch | Berlin | |
Germany | Universitätsklinikum Carl Gustav Carus | Dresden | |
Germany | Universitätsklinikum Essen | Essen | |
Germany | Universitätsklinikum Hamburg-Eppendorf | Hamburg | |
Germany | Medizinische Hochschule Hannover | Hannover | |
Germany | University Medical Center | Mannheim | |
Germany | Klinikum der Universität München Campus Großhadern | München |
Lead Sponsor | Collaborator |
---|---|
Heidelberg University | Hannover Medical School, Helios Klinikum Berlin-Buch, Klinikum der Universitaet Muenchen, Grosshadern, Medical University Innsbruck, Medical University of Graz, Medical University of Vienna, Novartis Pharmaceuticals, Universitätsklinikum Hamburg-Eppendorf, Universitätsmedizin Mannheim, University Hospital Dresden, University Hospital, Essen |
Austria, Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of Progression-free Survival | The diagnosis of progession is based on tumor measurements assessed 182 days +/- 32 days after start of treatment (with imaging date as reference date) and according to the RECIST Version 1.1 criteria based on a predefined set of target lesions and non-target lesions. | 6 Month | |
Primary | Rate of Progression-free Survival, Subgroup 1 Analysis | Rate of progression-free survival for Subgroup 1 categorizing the 12 participants who showed PFS after 6 months into cutaneous angiosarcoma versus visceral angiosarcoma The diagnosis of progession is based on tumor measurements assessed 182 days +/- 32 days after start of treatment (with imaging date as reference date) and according to the RECIST Version 1.1 criteria based on a predefined set of target lesions and non-target lesions. | 6 months | |
Primary | Rate of Progression-free Survival, Subgroup 2 Analysis | Rate of progression-free survival for Subgroup 1 categorizing the 12 participants who showed PFS after 6 months into primary angiosarcoma versus secondary angiosarcoma.
The diagnosis of progession is based on tumor measurements assessed 182 days +/- 32 days after start of treatment (with imaging date as reference date) and according to the RECIST Version 1.1 criteria based on a predefined set of target lesions and non-target lesions. |
6 months | |
Secondary | Overall Survival | Survival time of patient from start of treatment until death | from start of treatment until death within study's actual observation time for OS (22 months). | |
Secondary | Overall Survival, Subgroup 1 Analysis | Survival time of patients from start of treatment until death, Subgroup 1 categorizing 26 overall participants into 18 cutaneous angiosarcoma versus 8 visceral angiosarcomas | from start of treatment until death within study's actual observation time for OS (22 months) | |
Secondary | Overall Survival, Subgroup 2 Analysis | Survival time of patients from start of treatment until death, Subgroup 2 categorizing 26 overall participants into 13 primary cutaneous angiosarcoma versus 13 secondary angiosarcomas | from start of treatment until death within study's actual observation time for OS (22 months) | |
Secondary | Response Rate (RR) | Measurable skin lesions will be evaluated clinically and documented photographically, all other target lesions will be evaluated radiologically by CT or MRI according to RECIST Version 1.1.
RR is given as 'Best overall response" BOR" defined as CR (complete remission), PR (partial) remission), SD (stable diesease) and PD (progressive disease) or NE (not evaluated) and provided by absolute and relative frequencies |
determined every 8 weeks during first 6 month then every 12 weeks in follow-up period until progression or death or end of overall study observation period (22 months), then evaluated as BOR | |
Secondary | Response Rate (RR), Subgroup1 Analysis | Measurable skin lesions will be evaluated clinically and documented photographically, all other target lesions will be evaluated radiologically by CT or MRI according to RECIST Version 1.1.
RR is given as 'Best overall response" BOR" defined as CR (complete remission), PR (partial) remission), SD (stable diesease) and PD (progressive disease) or NE (not evaluated) and provided by absolute and relative frequencies for Subgroup 1 which is the analysis of cutaneous angiosarcoma versus visceral angiosarcoma |
determined every 8 weeks during first 6 month then every 12 weeks in follow-up period until progression or death or end of overall study observation period (22 months), then evaluated as BOR | |
Secondary | Response Rate (RR), Subgroup 2 Analysis | Measurable skin lesions will be evaluated clinically and documented photographically, all other target lesions will be evaluated radiologically by CT or MRI according to RECIST Version 1.1.
RR is given as 'Best overall response" BOR" defined as CR (complete remission), PR (partial) remission), SD (stable diesease) and PD (progressive disease) or NE (not evaluated) and provided by absolute and relative frequencies for Subgroup 2 which is the analysis of primary angiosarcoma versus secondary angiosarcoma |
determined every 8 weeks during first 6 month then every 12 weeks in follow-up period until progression or death or end of overall study observation period (22 months), then evaluated as BOR | |
Secondary | Adverse Events and Serious Adverse Events | Number of patients in which adverse events occur during treatment according to Common Toxicity Criteria for Adverse Effects, Version 4.0 | 30 days after EOS of last patient or end of overall study observation period (22 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 | |
Completed |
NCT01303497 -
Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas
|
Phase 2 | |
Recruiting |
NCT02625389 -
Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization.
|
Phase 4 | |
Completed |
NCT04293289 -
Boron Neutron Capture Therapy Using CICS-1 and SPM-011 for Malignant Melanoma and Angiosarcoma
|
N/A | |
Recruiting |
NCT05859074 -
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
|
Phase 1 | |
Not yet recruiting |
NCT02732678 -
Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Efficacy-tolerability Outcome in Patients With Locally Advanced or Metastatic Angiosarcoma: A Collaborative and Innovative Phase I-II Sequential Trial by the French Sarcoma Group (GSF/GETO)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04055220 -
Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
|
N/A | |
Recruiting |
NCT06375941 -
Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars
|
||
Recruiting |
NCT05799612 -
Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma
|
Phase 1 | |
Withdrawn |
NCT05116800 -
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
|
Phase 2 | |
Recruiting |
NCT01042379 -
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01786889 -
Identification, Molecular Epidemiology Angiosarcoma of the Liver France
|
N/A | |
Active, not recruiting |
NCT02834013 -
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03331250 -
Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
|
Phase 2 | |
Completed |
NCT02584309 -
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
|
Phase 2 | |
Not yet recruiting |
NCT06277154 -
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
|
Phase 2 | |
Withdrawn |
NCT04607200 -
AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma
|
Phase 2 | |
Completed |
NCT04518124 -
Propranolol in Angiosarcoma
|
Phase 2 | |
Recruiting |
NCT05961761 -
Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients
|
Phase 2 | |
Completed |
NCT00887809 -
Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
|
Phase 2 |